PDVSA recovers operatorship of Caribbean facilities alleviating export bottlenecks, says GlobalData
Following the recent announcement of ConocoPhillips and PDVSA agreement over a US$2bn legal arbitration that had led to the seizure of PDVSA assets in the Caribbean, Adrian Lara, Senior Oil & Gas Analyst at GlobalData, a leading data and analytics company, offers his view on the impact on the upstream sector:
“Recovering these Caribbean assets thanks to the agreement with Conoco, means PDVSA can load export cargoes at a faster pace and avoid bottlenecks that were already slowing down field production. Right now maximizing the level of exports is key in securing any revenue Venezuela can receive. Even if these cargoes pay for previous loans or barter for refined products shipments not having any issues in exporting whatever volume is available is crucial.
“However this does not mean the production decline in the country will stop since the rig activity and the field services are practically at their minimum or non-existent in some fields. The increased need for diluent to blend Orinoco Belt crude has also increased the operating expenditure of producing each barrel; currently most assets have a barely positive or negative post-tax cash flow.
“Furthermore, even at lower levels of oil production, exports to Asia will surely need to continue due to previous agreements in paying for loans. Indeed this reduces the available volume that can be sent to the US gulf coast refineries where heavy crude, such as the diluted crude from the Orinoco Belt, not only has a constant demand but means actual cash payments for PDVSA.
“With decreasing Mexican heavy crude exports and Canadian heavy oil sands still having logistic restrictions, the gulf refineries are a safe outlet for Venezuelan crude, if PDVSA manages to deliver its diluted crude there instead of Asia, we can see a relative stable level of exports to the US. However, all this ultimately depends on stabilizing the country’s decline which is proving to be very difficult.”
ENDS
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
email: pr@globaldata.com
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
GlobalData.com | LinkedIn | Twitter
About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
Recent measles outbreaks in 21 states and the District of Columbia are causing a new stir surrounding vaccines, and the choice of many parents not to vaccinate. In his new book, How to End the Autism Epidemic, autism advocate J.B. Handley dives into the scientific research linking vaccines to immune activation events in the brain. However, unlike many other activists, Handley does not advocate to stop vaccinations. Instead he is a proponent for testing children before they are given the shots.
"Since the early 1980's, the number of vaccines given to children has nearly quadrupled, and the autism rate has gone up more than 30,000 percent during the same time period. For American children, the current autism rate is 1 in 36. This epidemic is real," says Handley.
What The Book Is About
· Tells the story of Handley's own family and their journey through autism. Handley's son Jamison began developing symptoms associated with autism around two months old, after his first round of vaccinations.
· Breaks down autism recovery and the current research that supports faster diagnosis and treatment
· Dives into the current scientific research, analyzing herd immunity, vaccinations and immune activation events
About the Author
J.B. Handley (www.jbhandleyblog.com) is the co-founder and chairman of Generation Rescue, a nonprofit organization focused on helping children recover from autism that was inspired by the journey of his son, Jamison, who was diagnosed with autism in 2004. He is also the coproducer of the documentary film Autism Yesterday and the cofounder of the Age of Autism blog. He is an honors graduate of Stanford University and lives in Portland, Oregon with his wife and three children.
canfitpro World Fitness Expo unites thousands of new and returning enthusiasts for 25th anniversary event
World’s largest fitness conference and trade show took place August 8-12 at Metro Toronto Convention Centre
TORONTO, ON — Over 10,000 fitness lovers gathered at the Metro Toronto Convention Centre this past weekend to celebrate all things health and wellness.
canfitpro World Fitness Expo gave attendees a sneak peek at the latest trends, offered informative wellness and nutrition sessions and introduced high-powered workouts led by the industry’s biggest names. Fitness superstar Jillian Michaels,
World of Dance judge Derek Hough and
Jersey Shore: Family Vacation’s Vinny Guadagnino were just some of the celebrity talent on board to celebrate the 25
th anniversary event.
In its milestone year, canfitpro World Fitness Expo opening ceremonies paid tribute to its long list of veteran attendees, some spanning back to its inception 25 years ago. With attendance growing more and more each year, canfitpro World Fitness Expo educates and inspires people of all ages, aiming to provide exceptional learning experiences to take beyond the expo. Over the course of the weekend, both industry professionals and newcomers alike got the opportunity to learn from their peers and take home industry insights from some of the biggest names in fitness.
“We are thrilled to have celebrated this milestone year with some of the top talent in the fitness and health sphere,” said Nathalie Lacombe, vice president of canfitpro. “From jam-packed meet and greets to insightful educational seminars and intensive workouts,canfitpro World Fitness Expo is known for providing cutting-edge sessions and industry expertise. We were happy to continue that tradition and embrace the latest innovations in the industry this year.”
The event also included Expo Hall, a two-day exhibition with hundreds of vendors offering unmatchable deals on products and services that support healthy and active lifestyles. Select exhibitors hosted fitness competitions with big ticket rewards. REPerformance gave one lucky attendee $1,000 for 1,000 push-ups and The Canadian Physique Alliancehosted a competition in search of the next great bodybuilder. Highlight exhibitors also included Canadian-made functional clothing company, RYU Apparel; high protein, low sugar snacks by SimplyProtein; and world-renowned obstacle race events, Spartan Race Inc.
The largest industry conference and trade show, canfitpro World Fitness Expo is held every August in Toronto and welcomes delegates from all over the country to preview the latest trends, take part in health and wellness workshops and experience high-level fitness sessions. For more information, visit worldfitnessexpo.com or canfitpro.com/en.
Website: www.worldfitnessexpo.com
Twitter: @canfitpro
Instagram: @canfitpro
Facebook: @canfitpro
Hashtag: #canfitpro #worldfitnessexpo
About canfitpro
canfitpro is the largest provider of education in the Canadian fitness industry. Founded in 1993, canfitpro delivers accessible, quality education, certifications, events and membership services. canfitpro's over 24,000 members include some of the world's finest fitness professionals, health club operators, industry suppliers, and fitness consumers.
Look sharp and stay comfortable Canada:
Van Heusen launches functional men’s business wear at Hudson's Bay
TORONTO – Following the recent launch of
Van Heusen’s first-of-its-kind partnership with Ultimate Fighting Championships (UFC) and renowned fighters
TJ Dillashaw and
Stephen Thompson, the heritage brand today announced its arrival at Hudson’s Bay stores across Canada. Featuring a selection of their best-selling functional men’s apparel, the
Flex and Traveler Collections, consumers can now shop for their closet-staples at Hudson's Bay.
“We are excited to re-introduce Canadians to the beloved Van Heusen brand” said Richard Deck, President, PVH Canada Corp. “The Flex and Traveler Collections are wardrobe game-changers that seamlessly combine active and professional lifestyles. We are honoured to partner with The Hudson’s Bay for this launch and keep Canadians looking sharp and comfortable throughout the day.”
Van Heusen x UFC: Flex Collection
The Van Heusen Flex Collection includes dress shirts, pants and sport shirts perfect for the newest generation of ambitious Van Heusen men seeking functional yet stylish work apparel.
Van Heusen Traveler Dress Shirt
The
Van Heusen Traveler Collection offers a versatile and hassle-free lineup for men on-the-go, with no ironing needed. The collection also offers innovative odour-shield technology to help keep a fresh and clean scent all day. Pieces are available starting at $35.
Flex and Traveler Collections are available at Hudson’s Bay stores across Canada and will be available online, September 2018.
Website: VanHeusen.com
Twitter: @VanHeusen
Instagram: @VanHeusenStyle
About PVH Corp.
With a history going back over 135 years, PVH has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. With over 36,000 associates operating in over 40 countries and nearly $9 billion in annual revenues, PVH owns the iconic CALVIN KLEIN, TOMMY HILFIGER, Van Heusen, IZOD, ARROW, Speedo*, Warner’s, Olga and Geoffrey Beene brands, as well as the digital-centric True & Co. intimates brand, and market a variety of goods under these and other nationally and internationally known owned and licensed brands.
COMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-resistant Depression
LONDON, Aug. 22, 2018 /CNW/ - COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory approvals for the trial have already been given in the UK, the Netherlands and Canada.
(Logo: https://mma.prnewswire.com/media/733890/COMPASS_Pathways_Logo.jpg )
The trial is a phase IIb dose-ranging study with 216 patients taking part in 12 to 15 research sites across Europe and North America. It will begin in the UK later this month and sites in other countries will join the trial as further regulatory approvals are received.
Psilocybin therapy combines a dose of psilocybin (a psychoactive medicine and the active ingredient in "magic mushrooms") with psychological support, and has shown promising signals of efficacy and safety as treatment for depression in academic studies in the UK and US. If the trial is successful, it will be followed by phase III studies.
George Goldsmith, Chairman and Co-founder of COMPASS Pathways, said, "We are excited to be starting this landmark trial which has the potential to transform lives. Depression is the leading cause of ill-health and disability worldwide, and treatment-resistant depression affects more than 100 million people. It is a huge unmet need and the trial will teach us more about how this new approach might address it."
Ekaterina Malievskaia, Chief Medical Officer and Co-founder of COMPASS, said: "The design of this study has been a truly collaborative effort, with scientists, clinicians, patient representatives and regulators from Europe and North America working together with the goal of helping patients suffering with treatment-resistant depression."
About COMPASS Pathways
COMPASS Pathways is a life sciences company, founded in 2016 to accelerate patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through a late-stage clinical trial in Europe and North America for patients with treatment-resistant depression. We will improve mental health through the development of new patient care pathways, based on advances in neuroscience, psychotherapy, psychopharmacology, and technology.
http://www.compasspathways.com
SOURCE Compass Pathways
NEW ATHLETIC WEAR BRAND, TEMPLE ATHLETIC AIMS TO BUILD A BETTER, HEALTHIER YOU BY BEING A BETTER, HEALTHIER SPORTSWEAR COMPANY
|
|
| - A new, locally made sportswear brand creates a better, healthier you while also promoting a cleaner environment – |
|
|
TORONTO (August 22, 2018) - Launching Today on Kickstarter, The Temple Athletic Co. the NEW, industry changing sportswear brand for men and women that is designed using only superior performance fabrics free of dangerous toxins. |
|
| Dangerous toxins and chemicals used in the weaving, dyeing and treatment processes of today’s leading sportswear brands have been linked to various illnesses, including contact dermatitis, hormone disruption, learning disabilities and cancer (REPORT). When an individual exercises, these toxins absorb into the body from friction and heat through sweat.
All Temple Athletic collections are made locally, using superior performance fabrics that are lightweight, moisture wicking, anti-bacterial, anti-odour, provide UV protection all with zero dangerous toxins. Crafted in the world’s most advanced fabric mills, using only the highest human and environmental production standards in the world.
Not only is Temple Athletic safe for those who wear it, but it also promotes a cleaner Earth, in which the apparel and footwear industry are the second worst global polluters behind oil & gas.
Our vision? It’s simple. We want to help build a better, healthier You by being a better, healthier sportswear company.
The Temple Athletic Co. invites you to join their community in telling their story, to educate and to provide the consumer with a healthy sportswear alternative.
Good for your body. Good for the planet. Locally made. |
|
| Temple Athletic products will be offered at a ‘pre-order promotional rate’ starting August 22nd on Kickstarter. All customers will also receive unlimited access to a media library curated by Temple Athletic Brand Ambassadors providing the most current information about diet, health and exercise direct from the health & fitness community. |
|
| CONNECT WITH US
Instagram: @thetempleathletic Facebook: Temple Athletic Company Kickstarter Campaign: The Temple Athletic Co. Website: www.templeathletic.com
Hashtag: #whatareyouwearing? #cleansweat |
|
ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
TORONTO and CAMBRIDGE, MA, Aug. 22, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.Wainwright & Co. The conference is being held on September 4-6, 2018 at the St Regis New York Hotel in New York City.
Eugene Williams, Executive Chairman of ProMIS Neurosciences will provide a corporate overview in the Fontainebleau Foyer on Thursday, September 6, 2018, at 2:10 p.m. EDT, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor and would like to attend the Company's presentation please visit www.rodmanevents.com to register for the conference. Once your registration is confirmed, you will be able to log into the conference website to request a one-on-one meeting.
A live webcast of ProMIS' presentation may be accessed through the company website www.promisneurosciences.com, via this link and from the conference site at www.rodmanevents.com. Please log on to the webcast prior to the scheduled event to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on ProMIS' website following the presentation.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please visit us at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc.
MagVenture, Inc: FDA Clears 3-Minute, Non-Pharmaceutical Depression Treatment
ATLANTA, GA, Aug. 22, 2018 /CNW/ - For people suffering from severe depression, the road to remission just became a lot shorter: The treatment is known as Transcranial Magnetic Stimulation (TMS), and MagVenture has now, as the only TMS provider in the US, received FDA clearance for a newer and much faster treatment protocol which will cut down treatment time to just 3 minutes per session*. Before that, the required treatment time per session was up to 37 minutes.
(Photo: https://mma.prnewswire.com/media/733551/Picture_magventure.jpg )
TMS has been FDA cleared for treatment-resistant major depressive disorder since 2008. Since then, over 1,000 psychiatric clinics have emerged in the US. Most private health insurance companies also cover the treatment. The relatively long treatment sessions have, however, not only limited the treatment capacity for TMS practices but also hindered a more widespread dissemination. Until now, each session has been up to 37 minutes long, with 20-30 sessions needed in total. The new treatment form, which is known as Theta Burst Stimulation (TBS), offers one significant advantage: Time. A TBS treatment session lasts only 3 minutes and thus has the potential to revolutionize the clinical field of TMS.
"We have named it "Express TMS[®]" because that's what it is: a treatment which is just as safe and effective for the treatment of depression as conventional TMS, only much, much faster. We are happy and proud to be the first in the US to receive an FDA clearance for this revolutionary treatment which is backed up by substantial scientific evidence. Our current treatment system, MagVenture TMS Therapy, can easily be upgraded with the new Express TMS option. This will enable our many customers to treat far more patients per day without having to invest in another TMS device. For people needing treatment, this will also be a huge benefit, as treatment will now take up less of their time," says Kerry Rome, Vice President of Sales, MagVenture Inc.
The new FDA cleared treatment protocol, currently only offered by MagVenture, is based on a new clinical study, named the THREE-D trial, and led by a partnership of three leading research hospitals in Canada (CAMH, UHN, and UBC). It is the largest, double-blinded, randomized TMS trial to date, with 414 participants suffering from major depressive disorder. Response/remission rates were 33% for those receiving the TBS protocol, whereas 50% had an improvement in their depressive symptoms. These rates are similar to the standard, longer TMS protocol. The article was published in The Lancet in 2018.
What is TMS?
Transcranial Magnetic Stimulation, or TMS, is an effective, non-invasive alternative for the large number of patients not responding to medication. It does not require anesthesia - and is not to be confused with ECT (Electro Convulsive Therapy).
MagVenture TMS Therapy delivers magnetic pulses to stimulate nerve cells in the part of the brain controlling the mood. The rapid change in the magnetic field induces a current, and if the current induced is of sufficient amplitude and duration, it will excite neurons.
Both TMS and TBS are based on these principles. The difference lies in the way the magnetic pulses are delivered.
MagVenture is the only company with an FDA cleared Theta Burst solution for the treatment of depression, "Express TMS"®.
MagVenture's FDA clearance: *The MagVita TMS Therapy system is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
FDA clearance
MagVenture is a Danish medical device company, established in 2007, specializing in non-invasive magnetic stimulation systems for the treatment of major depressive disorder. As we are founded in research, we have collaborations with most of the leading TMS researchers in the world, in the areas of neurophysiology, neurology, cognitive neuroscience, rehabilitation and psychiatry.
Our advanced series of coils and magnetic stimulators are sold on the world market through direct sales subsidiaries in Germany, the UK and the USA, and through a global network of distributors in Europe, Asia, Middle East and the Americas.
http://www.magventure.com
SOURCE MagVenture, Inc
Powerful Story Shares One Woman's Struggle To Overcome Abandonment And Abuse
Raleigh, NC, August 21, 2018 ― Deja' was dealt a losing hand, and no one would have blamed her for simply accepting her fate. Her father died before she was born, and her mother chose drug addiction over her daughter. With loneliness consuming her, Deja' could have folded. Should have folded. But instead, she learned how to recycle her pain, and she began drawing from every source of positive influence that entered her life: a God-loving grandmother, a supportive godmother and a street-savvy godfather who taught her how to redirect her pain and survive in this world.
But the challenges just kept coming, and Deja' encountered countless betrayals and abuses along the way, which lead to an unhealthy marriage, and ultimately, a pattern of unhealthy relationships with men that lasted for several years. Aware that she is repeating a family cycle of poor choices, Deja' needs to rally what's left of her strength and determination to break that cycle. Will her fortitude be enough? Or will this final test break her spirit once and for all?
Overcoming the Hand You Were Dealt is the powerful new book from Kisha Taylor. Cultivated from her personal experience with abandonment, Overcoming weaves an authentic and captivating story of struggle, pain, hope and faith that culminates in a heartwarming climax of healing and restoration.
In addition to the book, Taylor's website, lifeunlimited1.com, enables her to continue her passion for women's emotional health, with courses that tap into the warrior in every woman, that cover abandonment issues and that help survivors understand why they act and feel the way they do. The website also houses inspirational items like T-shirts and mugs with messages of empowerment, and a blog with videos and messages of encouragement.
Author Kisha Taylor was born in Brooklyn, NY, and from a young age, she learned how to navigate the real world of hard knocks. She attended Binghamton University and Baruch College, where she studied accounting and psychology. She became counsel to many, sharing principles on surviving abuse, overcoming life's challenges, healthy ways of handling personal mistakes and how to not surrender to self-defeat.
She is most proud of the lives her journey has impacted, as well as the happiness, confidence and emotional health she now has, which enables her to be a testament of, "You can, if you just don't give up.”
To read more from Taylor, or to view her motivational videos, please visit www.lifeunlimited1.com.
Overcoming the Hand You Were Dealt
Pendium publishing
Release date: February 5, 2018
ISBN-10: 1944348409
ISBN-13: 978-1944348403
Available at www.lifeunlimited1.com, Amazon.com, and all other online outlets.
Excerpts from Reviews:
"… Every woman can relate to the situations in this book.”
"… Anyone that reads it would benefit from it. … It's definitely a self-help book.”
BOCA RATON, Fla., July 24, 2018 /PRNewswire/ -- German-based Sveru Sport is bringing its vegan-friendly Amino4u capsules and homogenous powder supplements that contain all eight essential amino acids to e-commerce site www.vitabeauti.com.
The body can't make all the essential amino acids it needs so Amino4u has made it easy to get your body what it needs with vegan amino powder and capsules. Amino acids are necessary for functions including repairing tissue, removing waste deposits in the body's metabolic process and other processes which benefit muscle, bone, skin and hair health.
"Amino acids are crucial to movement, strength and agility," Sveru Sport CEO Sven Rueprich said. "They are the building blocks of protein, and proteins are involved with almost all biological functions. They are also a major component of cells, muscles and tissues. So, whether you are an athlete looking for gains, someone wanting to make their hair stronger or just looking for better nutrition, Amino4u is an easy solution."
These amino acids are in the cleanest, purest form, without binders or other additives. The supplements are also suitable for people with gastrointestinal and insulin problems, including diabetics who require Arginine to increase insulin sensitivity.
It's also easy on the digestive tract. "Amino4u guarantees easy digestion, without any pain or bloating feeling, due to its design with split aminos," added Rueprich."
Both Amino4u powder and capsules are hypoallergenic. The supplements take just 23 minutes to fully enter the bloodstream, where it begins to produce regenerative effects.
For more information on Sveru Sport and Amino4u products, visit www.amino4u.de/en/.
